Aerie Pharmaceuticals CEO Vicente Anido's 2019 pay slips 18% to $5.5M
Aerie Pharmaceuticals reports 2019 executive compensation
By ExecPay News
Published: April 24, 2020
Aerie Pharmaceuticals reported fiscal year 2019 executive compensation information on April 24, 2020.
In 2019, six executives at Aerie Pharmaceuticals received on average a compensation package of $2.9M, a 27% decrease compared to previous year.
Average pay of disclosed executives at Aerie Pharmaceuticals
Vicente Anido, Jr., Chief Executive Officer, received $5.5M in total, which decreased by 18% compared to 2018. 60% of Anido's compensation, or $3.3M, was in option awards. Anido also received $362K in non-equity incentive plan, $773K in salary, as well as $1.1M in stock awards.
Thomas A. Mitro, Chief Operating Officer, received a compensation package of $2.8M, which decreased by 19% compared to previous year. 59% of the compensation package, or $1.7M, was in option awards.
John W. LaRocca, General Counsel, earned $2.5M in 2019, a 40% decrease compared to previous year.
Richard J. Rubino, Chief Financial Officer, received $2.5M in 2019, which decreases by 17% compared to 2018.
David A. Hollander, Chief Research and Development Officer, earned $2.1M in 2019.
Casey C. Kopczynski, Chief Scientific Officer, received $2M in 2019, which decreases by 16% compared to 2018.
Related executives
Vicente Anido
Aerie Pharmaceuticals
Chief Executive Officer
Richard Rubino
Aerie Pharmaceuticals
Chief Financial Officer
Thomas Mitro
Aerie Pharmaceuticals
Chief Operating Officer
Casey Kopczynski
Aerie Pharmaceuticals
Chief Innovation Officer, Head of Research and External Innovation
John LaRocca
Aerie Pharmaceuticals
General Counsel
David Hollander
Aerie Pharmaceuticals
Chief Research and Development Officer
You may also like
Source: SEC filing on April 24, 2020.